Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Klinikum Ludwigshafen Norvartis Pharma, Nuremberg, Germany Coordination center for clinical studies, Mainz, Germany |
---|---|
Information provided by: | Klinikum Ludwigshafen |
ClinicalTrials.gov Identifier: | NCT00562406 |
The primary objective of this pilot study is to compare the functional and anatomic outcomes of chronic macular edema secondary to branch retinal vein occlusion (BRVO) treated with argon laser photocoagulation versus intravitreal ranibizumab (Lucentis®) injection versus a combination of both.
Condition | Intervention |
---|---|
Macular Edema |
Drug: Ranibizumab Procedure: Laser photocoagulation |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES) |
Estimated Enrollment: | 30 |
Study Start Date: | November 2007 |
Estimated Study Completion Date: | November 2008 |
Arms | Assigned Interventions |
---|---|
1: Active Comparator
laser photocoagulation to the retina at the area of edema
|
Procedure: Laser photocoagulation
laser photocoagulation to the retina at the area of edema
|
2: Experimental
intravitreal injection of ranibizumab
|
Drug: Ranibizumab
intravitreal injection of 0.5 mg ranibizumab after randomisation, at week 4 and 8
Procedure: Laser photocoagulation
laser photocoagulation to the retina at the area of edema
|
3: Experimental
laser photocoagulation to the retina at the area of edema and intravitreal injection of ranibizumab
|
Drug: Ranibizumab
intravitreal injection of 0.5 mg ranibizumab after randomisation, at week 4 and 8
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Alireza Mirshahi, MD, FEBO | +49 621 503 ext 3051 | Mirshaha@klilu.de |
Contact: Lars-Olof Hattenbach, MD | +49 621 503 ext 3051 | Hattebach.lo@klilu.de |
Germany | |
RABAMES investigational trial site | Recruiting |
Ludwigshafen, Germany, 67063 | |
Principal Investigator: Lars-Olof Hattenbach, MD | |
Sub-Investigator: Alireza Mirshahi, MD, FEBO | |
RABAMES investigational trial site | Recruiting |
Freiburg, Germany | |
Principal Investigator: Nicolas Feltgen, MD | |
Sub-Investigator: Lutz L Hansen, MD, Prof. | |
RABAMES investigational trial site | Not yet recruiting |
Munich, Germany | |
Principal Investigator: Siegfried Priglinger, MD | |
Sub-Investigator: Thomas Kreutzer, MD | |
Sub-Investigator: Anselm Kampik, MD, Prof. | |
RABAMES investigational trial site | Recruiting |
Mainz, Germany | |
Principal Investigator: Norbert Pfeiffer, MD, Prof. | |
Sub-Investigator: Katrin Lorenz, MD | |
Sub-Investigator: Kramann Christina, MD |
Principal Investigator: | Lars-Olof Hattenbach, MD, Privatdozent | Dept. of Ophthalmology, Ludwigshafen hospital |
Study ID Numbers: | AU-06104G |
Study First Received: | November 21, 2007 |
Last Updated: | August 21, 2008 |
ClinicalTrials.gov Identifier: | NCT00562406 |
Health Authority: | Germany: Paul-Ehrlich-Institut |
Macular edema secondary to branch retinal vein occlusion |
Eye Diseases Vascular Diseases Retinal Degeneration Edema Macular Degeneration Thrombosis Macular Edema Signs and Symptoms |
Embolism and Thrombosis Embolism Retinal Vein Occlusion Neoplasm Metastasis Venous Thrombosis Retinal Diseases Retinal degeneration |
Cardiovascular Diseases |